ERBB2 and breast carcinoma: Reliable assessment of HER2 status and variations in formal HER2-positive lesions have become even more relevant after the identification of the clinical relevance of the HER2-low subgroup, which is estimated to constitute ~ 50% of all breast cancer patients [20].